Seelos Therapeutics Ownership
| SEEL Stock | USD 0.39 0.11 22.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Seelos |
Seelos OTC Stock Ownership Analysis
The company recorded earning per share (EPS) of 351.04. Seelos Therapeutics last dividend was issued on the 24th of January 2019. The entity had 1:16 split on the 27th of September 2024. Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.The quote for Seelos Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Seelos Therapeutics contact the company at 646 293 2100 or learn more at https://seelostherapeutics.com.Seelos Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Seelos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Seelos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Seelos Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mehra Raj over a month ago Acquisition by Mehra Raj of 2282262 shares of Seelos Therapeutics at 1.08 subject to Rule 16b-3 | ||
Mehra Raj over a month ago Acquisition by Mehra Raj of 75757 shares of Seelos Therapeutics at 1.32 subject to Rule 16b-3 | ||
O'connor Daniel J. over a month ago Acquisition by Oconnor Daniel J. of 50000 shares of Seelos Therapeutics subject to Rule 16b-3 | ||
Lian Brian over two months ago Insider Trading | ||
Smith Sandford D over six months ago Purchase by Smith Sandford D of 18200 shares of Seelos Therapeutics | ||
Richard Pascoe over six months ago Acquisition by Richard Pascoe of 1666 shares of Seelos Therapeutics subject to Rule 16b-3 |
Seelos Therapeutics Outstanding Bonds
Seelos Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Seelos Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Seelos bonds can be classified according to their maturity, which is the date when Seelos Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.